Thrombotic events in children differ from those in adults in epidemiology, pathophysiology,
and anatomical location. However, anticoagulation in children is mostly based on evidence …

This review is aimed at describing the unique challenges of anticoagulant prophylaxis and
treatment in children, and highlighting areas for research for improving clinical outcomes of …

A State of the Art lecture titled “What the direct oral anticoagulants (DOACs) trials did and
didn't tell us” was presented at the International Society on Thrombosis and Haemostasis …

While the need for anticoagulation in children has increased over the last decades, dose
regimens of currently used anticoagulants, including low-molecular-weight heparin (LMWH) …

Venous thromboembolism (VTE) is a rare, but life-threatening disease in those who have not
reached their adulthood. This condition is usually treated with heparin or low molecular …

Common treatment options for deep vein thrombosis and venous thromboembolism in the
pediatric population include unfractionated heparin, low molecular weight heparin, and …

With the increasing incidence of thromboembolism in children and improvement in
management for patients with medically complex diseases, expanded availability of safe …

Special aspects of anticoagulation in children include the different epidemiology of
thrombosis, developmental changes in the coagulation system, age-dependent …

Direct oral anticoagulants (DOACs) provide an attractive alternative for the management and
prevention of thrombosis in pediatric patients. With multiple ongoing and published pediatric …

ABSTRACT Background Direct oral anticoagulants (DOACs) represent a cornerstone of
venous thromboembolism (VTE) treatment in adults. Recently, randomized controlled trials …